Brief: Rapt Therapeutics Initiates Phase 2B Clinical Trial Of Ozureprubart In Patients With Food Allergies
27/10/2025 13:32
Oct 27 (Reuters) - Rapt Therapeutics Inc RAPT.O: RAPT THERAPEUTICS INITIATES PRESTIGE PHASE 2B CLINICAL TRIAL OF OZUREPRUBART (RPT904) IN PATIENTS WITH FOOD ALLERGIES Source text: ID:nGNXbJgTmd Further company coverage: RAPT.O ((Reuters.Briefs@thomsonreuters.com;))